Citius Oncology, Inc. cash flow statement CTOR

In fiscal 2025, which ended Sep 30, 2025, Citius Oncology, Inc. used $5.5 million of cash from operations, down 4446.6% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Sep 30, 2025
FY 2024
Sep 30, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Operating
Stock-based compensation
13
8
+11.0%
7
—
—
Operating cash flow
—
-5
-4446.6%
0
+121.0%
-1
-1153.6%
-0
Investing
Investing cash flow
—
-6
-15.0%
-5
-278.8%
-1
+98.0%
-67
Financing
Financing cash flow
—
15
+211.2%
5
+192.7%
2
-97.5%
68
Change in cash
Net change in cash
—
—
—
-0
-188.7%
0
Ratios
Cash conversion
—
—
—
-0.25x
-0.13x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CTOR (Nasdaq)
Fiscal year ends
September 30
Incorporated in
DE
Headquarters
Cranford, NJ
SEC filer status
, Emerging growth company
SEC CIK
1851484
Former names
TenX Keane Acquisition (until Aug 5, 2024)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.